Formulation Development and Evaluation of Ubidecarenone Chewable Tablet

Abstract

Background: Coenzyme Q10 has a role in mitochondrial transport system and can be utilized as a supplement in migraine prevention. This study's objective is to assess Coenzyme Q10's effectiveness when used in conjunction with conventional medications to prevent migraines. Adding 300mg of coenzyme Q10 each day to prescription medications, while another group of patients continued receiving standard care. Over the course of a three-month treatment period, data on attack frequency, headache pain intensity, monthly migraine days, and associated symptoms like nausea, vomiting, phonophobia, and photophobia were analyses. Ubidecarenone, a medicinal component. The goal is to produce Ubidecarenone in a 300 mg chew-able tablet form. In vitro release studies and organoleptic properties, such as taste and flavour, will be evaluated. investigations in the early stages, tests for medicine excipient compatibility, and analyses of the water content Quality Assurance for the Process Hausner's Ratio, Bulk Density, Tapped Density, Comprehensibility Index, and Angle of Repose for calculating derived properties for medications and mixtures. ingredients that have been optimised for their concentrations, such as tastes, sweeteners, disintegrants, wetting agents, glidants, and lubricants. putting the best possible ingredients together to make a chew able pill. Evaluation of chewable tablets for post compression parameters including uniformity of weight, thickness, hardness, brittleness, friability, dissolution, assay, and in vitro drug release properties. An evaluation of the optimised batch's palatability is required. The intention is to create chewable tablets of ubidecarenone. Method: The wet granulation method is used to make chewable tablets of ubidecarenone. Mannitol is used as a diluent, crospovidone as a disintegrant agent, sodium starch as a disintegrate agent, saccharin sodium as a sucrose sweetener, orange flavour, peppermint oil as a flouring agent, and colloidal silicon dioxide as a gliding. The Ubidecarenone (300 mg) is one of the best first-line treatments for migraine prevention.